Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Since 2016 drug developers have spent $23.6bn in-licensing cancer projects, almost half of the sector’s up-front bill.
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
The data were statistically significant, but the market had been hoping for more.
Success in a study in essential tremor is marred by a high rate of adverse events and patient dropouts.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.